论文部分内容阅读
目的探讨头孢吡肟为主治疗非菌血症型下呼吸道铜绿假单胞菌感染的疗效和安全性。方法选择经痰培养确诊的76例患者、分成头孢吡肟组(A组)36例,以头孢吡肟4 g/d,头孢他啶组(B组)40例,用头孢他啶6 g/d,均静脉推注,疗程21 d;联用药物均为妥布霉素160 mg/d,肌内注射,疗程10 d。结果A、B组临床有效率分别为83/%、78%,细菌清除率分别为79%、70%,差异均无统计学意义(P>0.05)。2组在用药过程中无一例出现严重肾、耳毒性及其他副反应。结论4 g头孢吡肟联合160 mg妥布霉素治疗非菌血症型下呼吸道铜绿假单胞菌感染是安全和有效的,能提高治愈率,值得推广应用。
Objective To investigate the efficacy and safety of cefepime in the treatment of non-bacteremic lower respiratory tract Pseudomonas aeruginosa infection. Methods Sixty-six patients diagnosed by sputum culture were divided into cefepime group (group A) 36 cases, cefepime 4 g / d, ceftazidime group 40 cases, ceftazidime 6 g / d, Bolus, course of treatment 21 d; combination of drugs are tobramycin 160 mg / d, intramuscular injection, treatment of 10 d. Results The clinical efficacies in groups A and B were 83% and 78%, respectively. The bacterial clearance rate was 79% and 70% respectively, with no significant difference (P> 0.05). No severe renal, ototoxicity and other side effects occurred in the two groups during the course of medication. Conclusion 4 g cefepime combined with 160 mg tobramycin is safe and effective for the treatment of non-bacteremic lower respiratory tract Pseudomonas aeruginosa infection, which can improve the cure rate and is worth popularizing.